Fundraising FoxMethuselah Foundation
FoundationSpringfield · Seed · 16 people tracked
Find your way into Methuselah Foundation
Sign up to see every warm intro you have to Methuselah Foundation
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Methuselah Foundation team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
The Methuselah Foundation pursues a mission-first approach to extending healthy human lifespan, framing its work around a falsifiable goal of making 90 the new 50 by 2030. Rather than measuring return on investment, it emphasizes 'return on mission' — reducing human suffering and hastening medical breakthroughs. The foundation identifies, tests, and funds high-leverage interventions that produce near-term progress and compounding long-term effects in aging research. It treats aging as both an engineering and cultural challenge, and backs early-stage people and projects, offering incubation and strategic services to help them advance longevity science.
Source: firm website, verified Oct 2, 2026.
Team · 16 people
from the firm's website
What they invest in
from 5 of 11 portfolio companiesBiotech ×5Deep Tech ×4Healthtech ×3Medical Devices ×3Digital Health ×1New Materials ×1
HQs:United States×5
Investments · 11 tracked
founders shown can be your intro path
OncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity.
BiotechDeep TechHealthtechSeattle, US
Matt Scholz(Executive Officer, Director)inJohn Lewis(Executive Officer, Director)inGary Hudson(Director)in
Co-investorsHelios CapitalMethuselah FundsChainFund CapitalInvesco
Repair Biotechnologies develops the Cholesterol Degrading Platform, a therapeutic approach for treating conditions caused by localized accumulations of excess cholesterol.
BiotechHealthtechMedical DevicesSyracuse, US
Guilherme Cherman Perdigao de Oliveira(Executive Officer, Director)Reason("CEO's full legal name is ""Reason""")Anthony Matthew Chow(Director)
BoardKelsey Moody(Director)
Co-investorsLong GamequadraScope Venture FundThynk Capital
Viscient Biosciences develops drugs by studying human 3D tissue models combined with multi-omics analysis to understand disease mechanisms.
BiotechDeep TechDigital HealthSan Diego, US
Keith Murphy(Executive Officer, Director)in
Co-investorsHarmonix FundMethuselah FundsThynk Capital
Volumetric Biotechnologies, acquired by 3D Systems in 2021, develops bioprinting materials and vascularized human tissue constructs.
BiotechDeep TechHealthtechMedical DevicesHouston, US
Jordan Miller(President)inBagrat Grigoryan(COO)in
Co-investorsGaingelsGoAhead VenturesHarmonix FundHelios CapitalJoyance PartnersJude Gomila+21 more
__Twitter.png)
X-Therma develops a proprietary peptoid-based technology that inhibits ice crystal formation to enable long-term sub-zero preservation and transport of cells, tissues, organs, and other biologics.
BiotechDeep TechMedical DevicesNew MaterialsRichmond, US
Xiaoxi Wei(Founder & CEO)inMark Kline(Executive Officer, Director)inJohannes Weggemann(Director)
Co-investorsAurum Venture PartnersDellin InvestmentsLIFTTMethuselah FundsPortfoliaVU Venture Partners+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Leucadia TherapeuticsMethuselah FundOisin TechnologiesOrganovoSilverstone SolutionsTurn Bio
Exits · 1
1 acquisitionsVolumetricacq. by 3D Systems
Portfolio news
latest coverage across their companiesFrequently asked questions
- How many investments has Methuselah Foundation made?
- Methuselah Foundation has 11 tracked investments, 1 of which have exited.
- What stage does Methuselah Foundation invest at?
- Methuselah Foundation invests at the Seed stage.
- What sectors does Methuselah Foundation focus on?
- Methuselah Foundation focuses on Biotech, Healthtech, Impact & Social Good, Longevity, Medical Devices.
- Where is Methuselah Foundation located?
- Methuselah Foundation is headquartered in Springfield, US.
- Who does Methuselah Foundation co-invest with?
- Methuselah Foundation most often shares deals with Methuselah Funds, Harmonix Fund, Helios Capital, among 19 tracked co-investors.
Media · Podcasts & interviews
featuring the teamThe Path to a 1000-Year Lifespan with Dr. Aubrey de Grey
InsideTracker · Aubrey de Grey
Progress with ending aging, with Aubrey de Grey
London Futurists · Aubrey de Grey
Dr. Aubrey de Grey, Ph.D. - President & Chief Science Officer ...
Progress, Potential, and Possibilities · Aubrey de Grey
Longevity Escape Velocity | Dr Aubrey de Grey Interview Series ...
Modern Healthspan · Aubrey de Grey
On Longevity Escape Velocity with Aubrey de Grey & Charles ...
Let’s Talk Longevity · Aubrey de Grey
Similar investors
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Everywhere Ventures is an early-stage venture firm that writes pre-seed checks and is backed by a community of founder and operator LPs.
The Dementia Discovery Fund (DDF), managed by SV Health Investors, is a family of specialized venture capital funds investing exclusively in companies developing or enabling novel therapeutics for dementia, including Alzheimer's Disease.